QURE uniQure N.V. Stock Quote

QURE [NASD]

Healthcare | Biotechnology | Netherlands

Index	-	P/E	-	EPS (ttm)	-3.75	Insider Own	1.00%	Shs Outstand	44.47M	Perf Week	-8.42%
Market Cap	1.71B	Forward P/E	-	EPS next Y	-1.48	Insider Trans	-12.25%	Shs Float	39.83M	Perf Month	-21.58%
Income	-165.80M	PEG	-	EPS next Q	2.01	Inst Own	95.00%	Short Float	7.23%	Perf Quarter	5.45%
Sales	6.10M	P/S	280.80	EPS this Y	-32.80%	Inst Trans	0.17%	Short Ratio	5.53	Perf Half Y	-14.61%
Book/sh	5.12	P/B	7.33	EPS next Y	-322.90%	ROA	-41.50%	Target Price	69.26	Perf Year	-43.69%
Cash/sh	6.12	P/C	6.13	EPS next 5Y	-	ROE	-59.60%	52W Range	34.38 - 71.45	Perf YTD	3.87%
Dividend	-	P/FCF	-	EPS past 5Y	-1.30%	ROI	-33.70%	52W High	-47.47%	Beta	1.26
Dividend %	-	Quick Ratio	8.60	Sales past 5Y	3.50%	Gross Margin	-	52W Low	9.16%	ATR	2.13
Employees	248	Current Ratio	8.60	Sales Q/Q	80.00%	Oper. Margin	-	RSI (14)	39.41	Volatility	3.67% 5.04%
Optionable	Yes	Debt/Eq	0.16	EPS Q/Q	-108.70%	Profit Margin	-	Rel Volume	0.70	Prev Close	38.08
Shortable	Yes	LT Debt/Eq	0.16	Earnings	-	Payout	-	Avg Volume	520.24K	Price	37.53
Recom	1.70	SMA20	-5.43%	SMA50	-13.30%	SMA200	-20.09%	Volume	362,989	Change	-1.44%

Jan-07-21

Upgrade

Guggenheim

Neutral → Buy

$62

Nov-24-20

Initiated

H.C. Wainwright

Buy

$80

Nov-11-20

Initiated

Berenberg

Buy

Nov-09-20

Initiated

Jefferies

Buy

$55

Nov-04-20

Initiated

Cantor Fitzgerald

Overweight

$65

Oct-23-20

Initiated

RBC Capital Mkts

Outperform

$61

Aug-25-20

Initiated

Raymond James

Strong Buy

$75

Jul-31-20

Upgrade

Robert W. Baird

Neutral → Outperform

$57

Jun-25-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$56

Jun-25-20

Downgrade

Robert W. Baird

Outperform → Neutral

$58

Jun-25-20

Downgrade

Mizuho

Buy → Neutral

$90 → $61

Dec-03-19

Initiated

Goldman

Buy

Dec-03-19

Initiated

Cowen

Outperform

Nov-05-19

Initiated

Credit Suisse

Outperform

Oct-11-19

Initiated

Stifel

Buy

Sep-25-19

Initiated

Bernstein

Outperform

$73

Sep-12-19

Initiated

Mizuho

Buy

Jul-30-19

Downgrade

Guggenheim

Buy → Neutral

Jul-08-19

Reiterated

Cantor Fitzgerald

Overweight

$81 → $94

Apr-12-19

Initiated

Piper Jaffray

Overweight

$80

Jan-06-21 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE ACCESSWIRE
Jan-04-21 11:27PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE Newsfile
Dec-29-20 08:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE ACCESSWIRE
Dec-26-20 04:43PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE Newsfile
Dec-23-20 11:00AM	QURE INVESTIGATION: Bronstein, Gewirtz & Grossman, LLC Announces uniQure N.V. Investigation ACCESSWIRE
04:20AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE PR Newswire
Dec-21-20 04:40PM	Is QURE A Good Stock To Buy According To Hedge Funds? Insider Monkey -16.19%
04:24PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives Investor's Business Daily
10:18AM	UniQure Hemophilia Therapy Placed on FDA Clinical Hold TheStreet.com
07:55AM	UniQure Plunges As FDA Slaps Clinical Hold On Hemophilia B Gene Therapy Study On Possible Liver Cancer Link Benzinga
07:05AM	uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program GlobeNewswire
Dec-18-20 12:14PM	The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals Zacks
Dec-17-20 09:42AM	4 Biotechs That Could Be Potential Acquisition Targets in 2021 Zacks
Dec-15-20 04:36PM	This Gene Therapy Stock Is Ablaze On Eli Lilly's $1.04 Billion Takeover Investor's Business Daily
Dec-08-20 07:00AM	uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology GlobeNewswire
Dec-07-20 04:05PM	uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B GlobeNewswire -5.65%
Dec-02-20 07:05AM	uniQure to Participate in Multiple Upcoming Industry Conferences in December GlobeNewswire
Nov-30-20 07:05AM	uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-19-20 04:37PM	Uniqure Hits Pay Dirt In Gene Therapy And The Biotech Stock Bounds Higher Investor's Business Daily +7.95%
09:10AM	uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B GlobeNewswire
Nov-12-20 11:01AM	Brokers Are Upgrading Their Views On uniQure N.V. (NASDAQ:QURE) With These New Forecasts Simply Wall St.
Nov-04-20 10:46AM	uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting GlobeNewswire +6.62%
07:05AM	uniQure to Participate in Multiple Upcoming Industry Conferences in November GlobeNewswire
Oct-29-20 10:55AM	The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically Simply Wall St.
Oct-27-20 10:25AM	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:05AM	uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress GlobeNewswire
Oct-26-20 11:54PM	5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month) Insider Monkey
03:44PM	Were Hedge Funds Right About Piling Into Uniqure NV (QURE)? Insider Monkey
Oct-19-20 12:31PM	UniQure (QURE) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks
Oct-13-20 07:05AM	uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingtons Disease GlobeNewswire
Sep-30-20 07:05AM	uniQure to Participate in Multiple Upcoming Industry Conferences in October GlobeNewswire
Sep-25-20 07:05AM	uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingtons Disease GlobeNewswire
Sep-23-20 10:28AM	3 Strong Buy Stocks That Are Flirting With a Bottom TipRanks -5.19%
Sep-15-20 09:06AM	Loss-Making uniQure N.V. (NASDAQ:QURE) Set To Breakeven Simply Wall St. -5.10%
Sep-03-20 07:05AM	uniQure to Participate in Multiple Upcoming Industry Conferences in September GlobeNewswire
Aug-31-20 10:21PM	Hedge Funds Cant Buy Enough Of Uniqure NV (QURE) Insider Monkey
08:56AM	Implied Volatility Surging for uniQure (QURE) Stock Options Zacks
Aug-26-20 10:44PM	5 Biotech Stocks That Could Be Worth a Look Barrons.com
07:05AM	uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development GlobeNewswire
Jul-30-20 10:25AM	UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:05AM	uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress GlobeNewswire
Jul-27-20 12:31PM	UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-08-20 12:38PM	Were Hedge Funds Right About Piling Into Uniqure NV (QURE)? Insider Monkey
Jun-25-20 08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga -21.76%
07:54AM	UniQure's shares fall on licensing deal for gene therapy MarketWatch
Jun-24-20 06:28PM	CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure PR Newswire -7.13%
04:05PM	uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy GlobeNewswire
Jun-19-20 07:05AM	uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingtons Disease GlobeNewswire
Jun-17-20 04:05PM	uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors GlobeNewswire
Jun-15-20 07:05AM	uniQure Announces Change for its 2020 Annual General Meeting of Shareholders GlobeNewswire
Jun-01-20 09:29AM	Moving Average Crossover Alert: uniQure Zacks
May-29-20 07:38PM	Hedge Funds Done Buying Uniqure NV (QURE)? Insider Monkey +6.57%
May-18-20 07:49AM	Analysts Have Just Cut Their uniQure N.V. (NASDAQ:QURE) Revenue Estimates By 16% Simply Wall St.
May-14-20 07:00AM	uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting GlobeNewswire
May-11-20 11:13PM	JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era Bloomberg
Apr-29-20 08:45AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:00AM	uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress GlobeNewswire
Apr-28-20 04:51PM	uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting GlobeNewswire
Apr-27-20 12:32PM	Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline Zacks
Apr-24-20 04:21PM	Why Sanofi CEO's Comments Lit A Fire Under Gene Therapy Stocks Investor's Business Daily +9.03%
Apr-21-20 10:47AM	Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet? Simply Wall St.
Apr-17-20 07:00AM	uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors GlobeNewswire
Mar-30-20 07:00AM	uniQure to Participate in Multiple Upcoming Investor Conferences in April GlobeNewswire
Mar-28-20 09:10PM	Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Mar-26-20 12:36PM	Biotech delays U.S. gene therapy launch due to outbreak, FDA discord American City Business Journals
07:00AM	uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B GlobeNewswire
Mar-18-20 06:01AM	Biotech pushes blood disorder cell therapy to clinic after $80M round American City Business Journals
Mar-03-20 07:00AM	uniQure to Participate in Multiple Upcoming Industry Conferences in March GlobeNewswire
Mar-02-20 05:45PM	UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates Zacks +5.65%
04:05PM	uniQure Announces 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
04:05PM	uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters GlobeNewswire
Feb-27-20 07:00AM	uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDIs 15th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire
Feb-26-20 08:41AM	Why Earnings Season Could Be Great for uniQure (QURE) Zacks
Feb-21-20 10:48AM	Before You Buy uniQure N.V. (NASDAQ:QURE), Consider Its Volatility Simply Wall St.
Feb-20-20 12:31PM	UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Feb-04-20 07:00AM	uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) GlobeNewswire
Jan-31-20 07:00AM	uniQure to Participate in Multiple Upcoming Industry Conferences in February GlobeNewswire
Jan-10-20 02:20PM	Cambridge startup raises $110M for re-doseable gene therapies American City Business Journals
Jan-07-20 12:12PM	uniQure (NASDAQ:QURE) Shareholders Have Enjoyed A Magnificent 1077% Share Price Gain Simply Wall St.
Dec-24-19 09:30AM	BioMarin Files BLA for Gene Therapy to Treat Hemophilia A Zacks
Dec-19-19 10:27AM	One particular field of drug development could dominate M&A in 2020 American City Business Journals
07:00AM	uniQure Announces Publication of Preclinical Data for AMT-130 in Huntingtons Disease Supporting Non-Selective HTT-Lowering Approach GlobeNewswire
Dec-17-19 09:11AM	5 Biotech Stocks That Have More Than Doubled This Year Zacks
07:02AM	Will uniQure Continue to Surge Higher? Zacks
06:00AM	Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-16-19 09:34AM	5 Biotech Stocks Set for Continued Rally in 2020 Zacks
Dec-08-19 04:00PM	uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B GlobeNewswire
Dec-06-19 09:33AM	The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
Dec-05-19 04:32PM	Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
10:12AM	4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
03:49AM	Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 09:42AM	Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 11:53AM	The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga +16.68%
Dec-02-19 07:00AM	uniQure to Participate in Multiple Upcoming Industry Conferences in December GlobeNewswire
Nov-30-19 07:02PM	Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Nov-22-19 10:16AM	Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
Nov-07-19 09:45AM	uniQure N.V. (QURE) Shares March Higher, Can It Continue? Zacks
Nov-06-19 09:16AM	uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-05-19 07:00AM	uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy GlobeNewswire
Nov-01-19 07:00AM	uniQure to Participate in Multiple Upcoming Industry Conferences in November GlobeNewswire

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, CFO, Managing Director	Dec 16	Option Exercise	7.53	12,501	94,133	277,738	Dec 21 08:12 AM
Kapusta Matthew C	CEO, CFO, Managing Director	Dec 16	Sale	48.41	12,501	605,173	265,237	Dec 21 08:12 AM
Kapusta Matthew C	CEO, CFO, Managing Director	Nov 19	Option Exercise	7.53	3,125	23,531	276,592	Nov 24 04:25 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Nov 19	Sale	45.18	11,355	513,019	265,237	Nov 24 04:25 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Nov 18	Option Exercise	7.53	3,216	24,216	283,780	Nov 20 04:58 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Nov 18	Sale	43.69	10,313	450,579	273,467	Nov 20 04:58 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Oct 14	Sale	35.86	5,250	188,256	280,564	Oct 16 04:10 PM
Gut Robert	Chief Medical Officer	Sep 21	Sale	39.12	4,352	170,250	41,523	Sep 22 09:48 AM
Kuta Alexander Edward III	Executive VP, Operations	Sep 18	Sale	41.18	2,230	91,831	56,860	Sep 22 09:54 AM
Kapusta Matthew C	CEO, CFO, Managing Director	Sep 16	Sale	40.66	7,500	304,939	285,814	Sep 18 01:41 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Aug 25	Sale	40.27	300	12,081	293,314	Aug 27 05:00 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Aug 19	Sale	39.11	4,300	168,175	293,614	Aug 21 04:32 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Jul 22	Sale	42.31	5,626	238,025	297,914	Jul 24 04:41 PM
Gut Robert	Chief Medical Officer	Jun 23	Option Exercise	39.12	26,875	1,051,344	72,750	Jun 24 04:21 PM
Gut Robert	Chief Medical Officer	Jun 23	Sale	70.00	26,875	1,881,250	45,875	Jun 24 04:21 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Jun 17	Sale	66.04	7,501	495,366	303,540	Jun 22 04:43 PM
Kapusta Matthew C	CEO, CFO, Managing Director	May 20	Sale	59.94	7,501	449,580	311,041	May 22 05:13 PM
KLEMT CHRISTIAN	Chief Accounting Officer	Apr 24	Option Exercise	26.41	2,250	59,423	59,268	Apr 28 04:29 PM
KLEMT CHRISTIAN	Chief Accounting Officer	Apr 24	Sale	60.00	2,250	135,000	57,018	Apr 28 04:29 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Apr 22	Option Exercise	7.53	9,376	70,601	327,918	Apr 24 04:46 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Apr 22	Sale	56.87	9,376	533,205	318,542	Apr 24 04:46 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Mar 18	Option Exercise	7.53	5,626	42,364	324,168	Mar 20 01:16 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Mar 18	Sale	41.48	5,626	233,352	318,542	Mar 20 01:16 PM
KLEMT CHRISTIAN	Chief Accounting Officer	Mar 04	Option Exercise	26.41	15,750	415,958	72,768	Mar 06 10:07 AM
KLEMT CHRISTIAN	Chief Accounting Officer	Mar 04	Sale	52.29	15,750	823,500	57,018	Mar 06 10:07 AM
Kapusta Matthew C	CEO, CFO, Managing Director	Feb 19	Sale	64.56	7,501	484,256	284,753	Feb 21 10:03 AM
Soteropoulos Paula	Director	Feb 05	Sale	60.95	2,122	129,332	2,423	Feb 05 01:19 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Jan 31	Sale	57.98	3,872	224,499	264,541	Jan 31 03:45 PM
Astley-Sparke Philip	Director	Jan 30	Sale	59.23	807	47,799	6,005	Jan 30 09:39 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Jan 30	Sale	59.31	23,583	1,398,646	268,413	Jan 31 03:45 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Jan 29	Sale	61.94	23,583	1,460,794	291,996	Jan 31 03:45 PM
Kaye Jack	Director	Jan 28	Sale	62.20	806	50,133	14,128	Jan 30 09:32 PM
Balachandran Madhavan	Director	Jan 28	Sale	62.20	807	50,195	6,005	Jan 30 09:23 PM
Soteropoulos Paula	Director	Jan 28	Sale	62.19	807	50,187	4,545	Jan 30 09:15 PM
van Deventer Sander	EVP, Research & Product Dev.	Jan 28	Sale	61.61	2,227	137,214	43,127	Jan 30 09:11 PM
SCHAFFER DAVID	Director	Jan 28	Sale	62.27	806	50,190	44,915	Jan 30 09:06 PM
KLEMT CHRISTIAN	Chief Accounting Officer	Jan 28	Sale	61.47	11,975	736,072	42,564	Jan 30 09:02 PM
Springhorn Jeremy P.	Director	Jan 28	Sale	62.19	807	50,190	6,005	Jan 30 08:57 PM
Meek David D.	Director	Jan 28	Sale	62.19	722	44,903	2,508	Jan 30 08:54 PM
Gut Robert	Chief Medical Officer	Jan 28	Sale	62.19	596	37,065	27,885	Jan 29 06:02 PM
Kuta Alexander Edward III	Executive VP, Operations	Jan 28	Sale	62.14	1,478	91,848	40,100	Jan 30 09:36 PM
Kapusta Matthew C	CEO, CFO, Managing Director	Jan 28	Sale	61.92	23,583	1,460,221	315,579	Jan 29 11:24 AM
Kapusta Matthew C	CEO, CFO, Managing Director	Jan 27	Sale	65.55	28,289	1,854,280	339,162	Jan 29 11:24 AM
Gut Robert	Chief Medical Officer	Jan 27	Sale	60.01	6,897	413,889	28,481	Jan 29 06:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience